Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.

This content is available also in other languages

x

This content is available also in other languages

Dr. Karen Huebscher

Chair of the Audit Committee
Member of the Nomination and Governance Committee

1963, Swiss and British citizen
Member since 2012, elected until 2024

Education

(IMD, Lausanne), Ph.D. Natural Sciences Molecular Biology (ETH Zurich), Masters Degree, Animal Sciences (ETH Zurich)

Professional background

2014 - 2021

CEO Solvias Group2, Headquarters in Kaiseraugst, Switzerland

Since 2012

Founder and Managing Director of Fibula Medical AG

2009 - 2011

Member of the European Commercial Operations Leadership Team and Site Head Novartis Vaccines & Diagnostics, Basel; Head Public Health and Market Access Europe (Marketing & Sales); Board member European Vaccines Manufacturer's Association, Brussels.

2006 - 2009

Executive Committee Member, Head M&A/BD&L Division Vaccines & Diagnostics

2000 - 2006

Group Head Investor Relations Novartis

1995 - 2000

Various roles with increasing responsibility in R&D and Finance

Financial Expertise

CEO of Solvias Group2; Head Investor Relations Group, Novartis from 2000 to 2006, reporting directly to CFO and Head of Treasury, Member of the Disclosure Committee Novartis, Head Mergers and Acquisitions, Division Vaccines & Diagnostics, Novartis

Other activities

Sandoz Group1, Vice-Chairwoman; BBI Group2, Member of the Board Nonprofit organizations: SMG (Swiss Management Association)2, Member of the Board; IMD2, Member of the Foundation Board

1 public company
2 private company